Elephas Live™ Platform

The Elephas Live™ Platform is an innovative solution designed to predict immunotherapy response in cancer patients by utilizing live tumor tissue. Traditional methods of assessing immunotherapy efficacy often fall short due to the biological complexity of live samples. With only 1 in 5 patients responding to current immunotherapy options, Elephas aims to bridge this gap through advanced technology.

Key Features

• Live Tumor Biopsy Assessment: The platform uses fresh tumor biopsies to maintain the tumor microenvironment, allowing for accurate evaluation of immunotherapy response.
• Advanced Imaging Technology: Capable of capturing data nondestructively at multiple time points, the platform predicts responses to immunotherapy before treatment begins and within 72 hours of biopsy.
• Proprietary Dataset: Elephas has curated an unprecedented dataset that facilitates research into the mechanisms of immunotherapy response, providing valuable insights for healthcare providers.
• Cloud-Based Data Access: The platform ensures secure, centralized data aggregation and analysis, empowering providers to make informed decisions about therapy selection.

Main Use Cases

The Elephas Live™ Platform is designed for deployment in pathology labs, enabling healthcare providers to predict the efficacy of standard care therapies using only a core needle biopsy. This capability is crucial for tailoring treatment plans to individual patients, ultimately improving outcomes in cancer care.

Benefits

By leveraging live tissue assessments, the Elephas Live™ Platform enhances the precision of immunotherapy selection, potentially increasing the response rates among cancer patients. The integration of advanced imaging and data analysis not only supports clinical decisions but also contributes to ongoing research in immunotherapy efficacy. With its focus on patient-centered care, Elephas is at the forefront of transforming cancer treatment methodologies.